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How did the study come about?
The rapid roll-out and subsequent scale-up of HIV
and antiretroviral services in resource-limited coun-
tries has seen a 47-fold increase in the number
of patients on antiretroviral therapy (ART) over
the 4 years prior to 2007.1 ART in low- and
middle-income countries has been shown to be simi-
larly effective in terms of individual immunological
and virological response as in high-resource set-
tings.2,3 However, challenges remain relating to bar-
riers to access,4 retention on treatment,5 early
mortality2,6,7 and limited and less well-tolerated
second-line regimens.8
In South Africa, home to 5.7 million HIV-infected
persons,9 HIV incidence and prevalence remain
high.10,11 With a large burden of disease constrained
by limited resources, the roll-out of ART in rural areas
illustrates the challenge, similarly faced by most
resource-poor settings, of managing this chronic
infectious disease. The national plan for HIV aims to
more than triple the number of individuals on ART
between 2007 and 2012,12 but if it is to be successful,
should be guided by appropriate programmatic evi-
dence to allow successful control of the epidemic.
The programme reported here was implemented as a
joint initiative by the Department of Health (DoH)
and the Africa Centre for Health and Population
Studies (http://www.africacentre.ac.za) in response
to the Comprehensive HIV and AIDS Care
Management and Treatment Plan in 2004.13 HIV
treatment and care are offered in 16 nurse-led
primary health-care (PHC) clinics and analysis will
add to the limited evidence of decentralized
models of health-care delivery.14 From inception,
the programme has adhered to South African and
KwaZulu-Natal guidelines for ART initiation, drug
regimens and follow-up.15,16 A secure database
system was developed to capture clinical and demo-
graphic information on individuals initiated onto
ART; this is regularly updated to contain follow-up
status and laboratory results (Table 1). The database
was established in 2007 when records from the start
of the programme in late 2004 were retrospectively
captured.
Study objectives and funding
The Hlabisa HIV Treatment and Care Programme is a
South African DoH programme, with additional sup-
port from the Africa Centre, funded from 1 August
2004 to 31 December 2006 by the Elizabeth Glaser
Paediatric AIDS Foundation (EGPAF) and since
1 May 2005 by the President’s Emergency Plan for
AIDS Relief (PEPFAR) and United States Agency for
International Development (USAID). The Wellcome
Trust funded Africa Centre provides additional data-
base management. PEPFAR sponsored staffing has
increased from 63 full-time staff in December 2007
to 123 in December 2008, working alongside
joint-trained DoH staff, and 540 home-based care vol-
unteers. The programme supports the integration of
HIV services into PHC, aiming to link treatment and
care with prevention services. The database serves
dual functions of providing feedback indicators to
funders and allowing internal evaluation of the
programme. The data collected allow examination of
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a wide range of clinical research questions including
how best to deliver HIV treatment and care through
PHC systems in rural South Africa and to assess how
that treatment and care impacts on the community.
Where is the study area and who
are in the sample?
The cohort includes HIV-infected people enrolled at
16 PHC clinics located in the predominately rural
Hlabisa sub-district of Umkhanyakude in northern
KwaZulu-Natal (Figure 1) with a population of
228 000. The local district hospital (Hlabisa) has 296
beds. Six of the DoH clinics, and 40% of patients, fall
within the Africa Centre Demographic Surveillance
Area (DSA), which has a population of 85 000
people in a 438-km2 area.17 The DSA population is
well characterized17—since 2000, data collection is
based on twice-yearly interviews with key-household
informants, annual household socio-economic sur-
veys, and, since 2003, an annual individual HIV sur-
veillance among adults. HIV prevalence in 2004 was
22% overall, peaking at 51% for females in the 25–29-
year age group and at 44% for men in the 30–34-year
age group.10 Locally, 62% of people have access to
electricity and 78% to piped water (not necessarily
in their homestead); 22% of children are orphans of
one or both parents;17 and 33% of those regarded as
household members in the surveillance area do not
reside within it.17 Information on these individuals
is collected within the Africa Centre Demographic
Information System (ACDIS; Table 1) and a random
12.5% are tracked each year for the HIV surveillance,
allowing a more complete understanding of the deter-
minants of HIV infection.18
After national roll-out in 2004, ART services were
only available from the hospital clinic. Later the
same year, services were expanded to include a
peri-urban clinic, (KwaMsane) (Figure 1), now the
largest ART clinic. By late 2006, six clinics were offer-
ing ART initiation; by late 2007, all 16 clinics offered
ART initiation and follow-up.
Diagnosis and treatment
The programme adheres to South African DoH guide-
lines on HIV diagnosis, ART eligibility, screening,
treatment regimens and follow-up.15 In adults and
children 418 months of age, a first positive rapid
HIV ELISA is confirmed by a second, and venous
blood ELISA is requested if results are discordant. If
the first rapid test is negative, repeat testing is recom-
mended every 6 months. Children <18 months old
are diagnosed by HIV DNA PCR after 6 weeks of
age; if negative, repeat testing is performed 6 weeks
after cessation of breastfeeding.16
Adults with WHO clinical stage 4 disease or CD4
count <200 cells/ml are eligible for ART.15,16
Provincial guidelines for children were updated in
2008 to include all four WHO disease stages and
new eligibility criteria for treatment initiation, partic-
ularly for infants, in line with findings from South
Africa that earlier treatment reduces childhood
mortality.16,19
Table 1 Data collected on those initiated on ART in the Hlabisa HIV Treatment and Care Programme, and on those in the
Africa Centre Demographic Information System
ART database
Basic details Age, sex, address, ID number, contact details, treatment clinic
Personal circumstance Grants received, employment, school attendance, number of
dependents
Tuberculosis (TB) record Previous history of TB, TB treatment at initiation, new episodes of
TB
ART record WHO clinical stage, Previous ART and/or PMTCT, ART regimen at
initiation, changes in ART regimen during treatment
Laboratory data Baseline and 6-monthly CD4 and HIV viral load, baseline haema-
tology and biochemistry
Clinic visits Monthly attendance
Africa Centre Demographic Information System (ACDIS)
Household demographics and socio-economic
data
Owner and members of households, latitude and longitudinal
position of homestead, household expenditure, asset ownership
Individual socio-economic data Age, sex, membership of household, education, employment,
receipt of grants
HIV status VCT history, dried blood spot for HIV testing and instant VCT
offered
Sexual behaviour Pregnancy history, contraceptive use, sexual activity
Deaths Location of death, description of circumstances, verbal autopsy
data
Births Pregnancy outcomes, delivery environment, birth weight
Migrations Details of destination and reason for migration
PMTCT, Prevention of Mother-to-Child Transmission; VCT, voluntary counselling and testing.
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Prior to ART initiation, adults and children are
screened for TB with symptom screen, sputum
acid-fast bacilli smear with or without culture and
chest X-ray.20 Other opportunistic and sexually trans-
mitted infections are diagnosed and treated appropri-
ately. Baseline blood tests include HIV viral load, full
blood count, creatinine, liver function tests and hep-
atitis B surface antigen. Chemoprophylaxis with
co-trimoxazole is used for adults and children eligible
for ART and children awaiting PCR results. The ART
regimen for adults and children 43 years of age and
410 kg in weight includes stavudine, lamivudine and
either efavirenz or nevirapine. Children <3 years of
age and <10 kg in weight are treated with stavudine,
lamivudine and ritonavir-boosted lopinavir.15,16
Anti-retrovirals are not available as co-formulations,
although liquids are available for paediatric use.
Adverse drug reaction reports and requests for indi-
vidual drug substitutions or regimen changes are
submitted to the provincial pharmacy office. Switch
to second-line therapy requires persistent viral load
55000 copies/ml in spite of documented adherence
595%; regimens are zidovudine, didanosine and
ritonavir-boosted lopinavir for adults and children
43 years of age; and zidovudine, didanosine and
nevirapine/efavirenz in children <3 years of age.15,16
Resistance testing is currently not available in the
programme.
How often have patients been
followed up and what has been
measured?
Patients attend three group education sessions fol-
lowed by individual counselling sessions prior to ini-
tiation. Patients must have identified a treatment
Figure 1 Hlabisa sub-district, northern KwaZulu-Natal, showing position of hospital with one on-site clinic and 15
peripheral clinics. The Hlabisa sub-district extends to the area at the bottom-right of the map to encompass Zwelenisha and
Mtubatuba clinics. The clinic at Khula village was only established in late 2009; previously patients accessed Kwamsane or
Zwelenisha clinics
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supporter and signed an agreement to attend clinic
and adhere to treatment. Patients can also consent
on the same form to their details being passed on to
a tracker should they default treatment. Initial
follow-up at 2 weeks assesses adherence and evidence
of toxicity (with nurse and counsellor). If the patient
is taking nevirapine, liver function tests are checked
at 2, 4 and 8 weeks; for zidovudine, full blood counts
are monitored at baseline, 4, 8 and 12 weeks. All
patients are seen monthly by a nurse and counsellor
for treatment collection, attending group followed by
individual counselling session prior to receiving med-
ication. No routine medical reviews are scheduled
after initiation but physicians visit each clinic at
least fortnightly and patients can be referred by ART
nurses. CD4 and viral load monitoring are performed
6-monthly and were initially analysed at centralized
provincial and district hospitals; with programme
expansion this process has become decentralized.
CD4 counts have been performed at Hlabisa hospital
since June 2008 and viral loads from mid-to late
2009. CD4 counts are analysed using Beckman
Coulter EPICS XL flow cytometer (Beckman
Coulter, Inc.); viral loads using Nuclisens EasyQ
HIV-1 assay (Biome´rieux) with a lower detection
limit of 25 copies/ml. All test results, including those
from other laboratories, are collated weekly into a lab-
oratory database and imported into the programme
database, allowing immunological and virological
follow-up information on all patients on ART, in addi-
tion to the clinical follow-up information (Table 1).
This system also provides information on patients
who have not yet met eligibility criteria for initiation
onto ART who are advised to have CD4 blood tests and
a nurse review for clinical staging every 6 months for
adults, and more frequently for children depending
on age and immunological/clinical status.
What has been found so far?
The programme has increased rapidly since inception
from 1800 people on ART by 31 October 2006 (after
2 years of ART programme) to 7576 by 31 December
2008. Further, from January 2008, CD4 results of
those accessing testing in the clinics have also been
documented (Figure 2). At the time of data censoring
(31 December 2008) the database contained results
for 19 566 individuals, 14 280 (73.0%) of whom were
female. The over-representation of females is a reflec-
tion of the local prevalence10 and continues to be
illustrated in those initiated onto treatment
(Figure 3). In 2004, in the ACDIS, overall, 27% of
female and 13.5% of male residents were HIV
infected.10 Aspects of equity and access to treatment
are currently being examined, but preliminary find-
ings suggest that males are only slightly less likely
to access treatment in comparison to females
(Personal Communication F Tanser, Africa Centre,
2009), contrary to recent reports that more attention
needs to be paid to ensure men access HIV treatment
and care.21,22
Figure 2 Cumulative total of persons who have accessed the Hlabisa HIV Treatment and Care Programme, showing those
initiated onto ART, those with CD4 tests but not yet initiated and those lost to follow-up or deceased
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There were 8832 adults with CD4 counts4200 cells/ml,
thus not yet eligible for treatment, and 2689 adults
with eligible CD4 counts but not yet started on ART
within our programme where there is no waiting
list for treatment (Table 2). There are multiple possible
reasons why this latter group has not started ART; they
may have moved out of the district, not returned
to access their CD4 results, were in the process
of being initiated, have started ART in the private
sector or local NGO programmes or have died.
Of the patients initiated, the median CD4 at initiation
was 118 cells/ml and plasma viral load 4.58 Log; most
people started on the efavirenz containing regimen
(Table 2). Among children, the median age at initiation
was relatively high, with half initiating treatment at
56 years of age. The majority of children were already
in WHO stage 3 or 4 at the time of initiation. However,
early results suggest success can be achieved with clin-
ical, immunological and virological improvement in
this rural paediatric cohort.23
In 2008, an average of 253 adults and 27 children
were initiated every month. In the paediatric cohort,
667 children (415 years old) had been initiated onto
ART by 31 December 2008 (8.8% of the total
initiated). Only 48 (7.2%) infants (41 year old)
were initiated on ART illustrating the enormous
challenges of identifying and treating young children.
Strategies have recently been implemented to increase
the overall number of children on treatment, con-
centrating on infants, including strengthening the
follow-up of mothers and infants in the local
PMTCT programme, ensuring PCR testing of infants
at 6 weeks of age and fast tracking of infected infants
for treatment.
The home-based care (HBC) branch of the pro-
gramme has increased significantly since October
2007, when service level agreements were formalized
between existing local care organizations and the
Hlabisa HIV Treatment and Care Programme. By
February 2009, 24 HBC organizations had been
recruited, with 540 volunteers covering 5800
patients.24 Carers visit community members after
referral from multiple sources including community
members, hospitals or clinics and local NGOs. Two
full-time professional nurses and a dedicated social
worker are also employed in the team.
Three interventions have been implemented in the
sub-district to increase access and uptake of HIV test-
ing. In the 16 fixed PHC clinics, between 1000 and
1500 people are tested and counselled for HIV each
month; and, from early 2009, the programme has
offered a Home and Mobile Testing Service employ-
ing seven counsellors, counsellor supervisors and
one full-time coordinator. It operates in areas outside
the DSA, offering rapid HIV testing in one of
two modalities; home-based VCT in individual
houses or VCT in a mobile unit. Secondly, the use
of Provider-initiated Testing and Counselling (PITC)
has been piloted in the sub-district.25 The pilot
resulted in a 3-fold increase in HIV testing rates in
the month after implementation.26 Currently, the
model has been expanded to a further five clinics
before roll-out to all 16. Finally, TB and HIV services
in the sub-district have been integrated so that there
is a physical proximity between the two services at
each clinic; all TB patients are offered an HIV test
and almost 90% accept.27,28
What analyses are planned for
the future?
The primary aim of the Africa Centre’s clinical
research on a programmatic level is to investigate
how best to deliver ART in this rural setting. On a
larger public health level, it is to relate the impact
Figure 3 Distribution by age and sex of those initiated on ART in the HIV Treatment and Care Programme
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Table 2 Characteristics of individuals enrolled in the Hlabisa HIV Treatment and Care Programme
Eligible and
on ART (n¼ 6909)
Eligible but
not on ARTa (n¼ 2689)
Not yet eligible
for ARTb,c (n¼ 8832)
No. or median No. or median No. or median
Adults (415 years old)
Age, years 35 (29–42) 33 (27–40) 30 (24–38)
Missing data 91 (3.4) 201 (2.3)
Sex, female 4688 (67.9) 1732 (64.4) 7253 (82.1)
Missing data 2 (0.07) 11 (0.1)
CD4 count at initiation (or at latest test), cells/ml 118 (58–175) 92 (36–148) 401 (298–552)
Missing data 528 (7.6)
Log10 viral load at initiation 4.58 (3.87–5.18)
Missing data 2890 (41.8)
WHO clinical stage at initiation
1 or 2 625 (9.0)
3 or 4 3068 (44.4)
Missing data 3216 (46.6)
Initiation drug regimen
d4T/3TC/EFV 5378 (77.8)
d4T/3TC/NVP 1419 (20.5)
Otherd 68 (1.0)
Missing data 44 (0.6)
Status (as of 31 December 2008)
Active 5759 (83.4)
Deceased 620 (9.0)
Lost to follow-up 348 (5.0)
Transferred out 182 (2.6)
Eligible and
on ART (n¼ 677)
Eligible but
not on ARTa (n¼ 207)
Not yet eligible
for ARTb,c (n¼ 262)
No. or median No. or median No. or median
Children (415 years old)
Age, years
<1 48 (7.2) 40 (19.3) 11 (4.2)
1–5 253 (37.9) 102 (49.3) 98 (37.4)
6–15 366 (54.9) 65 (31.4) 153 (58.4)
Sex, female 337 (50.5) 109 (52.7) 161 (61.5)
CD4 percentage at initiation (or latest test)
<1 year 17 (11–25) 18 (8.5–26.5) 42 (38–46)
1–5 years 17 (11–26) 14 (9–18) 28 (24–34)
6–15 years 16 (9–25) 9 (5–12) 24 (19–29)
Log10 viral load at initiation 3.65 (1.39–4.66)
Missing data 413 (61.9)
WHO clinical stage at initiation
1 or 2 114 (17.1)
3 or 4 479 (71.8)
Missing data 74 (11.1)
Status (as of 31 December 2008)
Active 595 (89.2)
Deceased 39 (5.9)
Lost to follow-up 18 (2.7)
Transferred out 15 (2.2)
Values are given as median (Interquartile range (IQR)) or n(%).
aDefined as CD4 count <200 cells/ml (adults) or CD4 eligibility criteria by age (children) prior to 1 October 2008 with no record of
initiation by 31 December (excludes 812 adults and 154 children with CD4 count results between 1 October and 31 December 2008).
bDefined only on CD4 criterion (5200 cells/ml) without clinical staging information.
cBased on latest CD4 count taken between 1 January 2007 and 31 December 2008.
dNon-standard regimens in patients transferred in from other programmes.
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of the programme in terms of impact on overall
population mortality. The impact of rapid expansion
must be quantified initially, and a series of analyses
are being conducted to examine clinical and virologi-
cal outcomes of adults and children on ART, time to
treatment failure and retention in the programme.
Approximately 40% of HIV-infected patients on treat-
ment in the sub-district live inside the Africa Centre’s
DSA and therefore have been linked (after obtaining
ethical approval) between databases allowing match-
ing of clinical, virological and immunological progress
and outcome with socio-economic, demographic and
household information.
There is a specific focus on co-infections, particularly
TB with calculations of incidence rate of new TB
infection in those on ART,29 as well as hepatitis B
co-infection.30 The research agenda aims to deter-
mine the impact of these co-infections and the best
way to integrate their management within the HIV
programme. A further database of all people
started on TB treatment in the sub-district has been
established for the Hlabisa TB control programme
of the DoH: this could also be linked to the ACDIS
and ART databases, with appropriate ethical
approval, to characterize the evolving TB epidemic
within rural South Africa, a country with the second
highest incidence of TB worldwide.31 The detailed
data on the local population from the ACDIS afford
the opportunity to explore mortality at the community
level and the impact of the ART programme on
patterns of deaths in adults and children.32 With
the exponential rise in numbers of people on ART,
the sustainability of ART programmes using current
approaches is debated. We intend to model differ-
ent approaches to follow-up of patients on treatment,
and explore these in terms of sustainability of
the programme and cost benefits. We also aim to
evaluate the success or otherwise of the local
PMTCT programme, and to use data from the ART
database to estimate access to services and impact
of treatment on HIV prevalence and incidence in
the population.
Quality of care and equity of access to treatment are
critical issues.33 Work is investigating clinic-level
determinants of quality of care and influences on out-
come, such as loss to follow-up and time from eligi-
bility for ART to initiation of treatment. A further
study examining equity to health care in three main
services—maternal health, TB and ART—is also in
progress; Researching Equitable Access to Healthcare
(REACH), and will use relevant data from the clinical
database.
What are the strengths and
weaknesses of the cohort?
The strengths of this cohort include its size, the quality
and quantity of data to describe it and the ability to
model the impact of the programme on the population
due to the detailed, longitudinal information available
about the community and the linkage between clinical
and surveillance data.32 Accurate characterization of
the cohort will allow understanding of the determi-
nants of outcomes, and implications for service delivery
in a rural population, which is likely to be applicable in
similar poor-resource settings. Quantifying outcomes in
a decentralized, mainly nurse- and counsellor-driven
service is different from many other reports, which
have described cohorts from specialist clinics in urban
settings. As the sustainability of programmes is
debated, ‘task shifting’ and decentralization of care
are likely to become increasingly common in HIV pro-
grammes to cope with increased numbers of people on
treatment.2,34,35
One of the main challenges common to all HIV
treatment cohorts is attrition rates;6,36 this is espe-
cially so in this area with high migration rates.
Using our linked datasets, we have another opportu-
nity to examine the outcomes of a large proportion of
people in the ART cohort and, through sensitivity
analysis, can provide more informed estimates of cov-
erage and outcomes including insights into the out-
come of those lost to follow-up in terms of mortality,
differentiating HIV-associated mortality from acciden-
tal mortality, non-HIV associated illness mortality or
simple migration of the household.
As this is primarily an HIV treatment cohort, we
have limited data on people who are eligible for, but
have not yet accessed, ART. Delayed ART initiation
has been reported to be a major cause of death in
South Africa,37 but, as mortality data on this group
are unavailable, we are unable to determine the pro-
portion of people who have died while awaiting
treatment.
In rural peripheral clinics it is not possible to main-
tain computerized records, and therefore data are
entered centrally. It is challenging to update records
at the central database from 16 peripheral clinics and
although new systems are in place, such as database-
generated monthly lists of patients who should be
attending clinic with check boxes for new develop-
ments (TB treatment, pregnancy, for example), it is
still possible that some details relating to people who
were initiated in the clinic may escape data entry. On
the other hand, the database provides a tool to
improve patient care and retention and is increasingly
used for that purpose.
In summary, this rural ART programme is well
placed to offer complex and wide-ranging analy-
ses on several aspects of ART in sub-Saharan Africa.
The support offered by the Africa Centre both
through external funding, database management,
population data from the demographic surveillance
and local scientific expertise allows it to be an effec-
tive and comprehensive treatment and care pro-
gramme as well as a cohort for analysis. In an era
when the consequences of rapid ART roll-out are
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starting to be felt, and the challenges of late presen-
tation with HIV persist, along with high and increas-
ing rates of infection such as TB, large rural
decentralized cohorts are needed to describe these
challenges, and the effect of interventions to address
them.
Can I get hold of the data?
Where can I find out more?
Further information about the data can be obtained
from the Africa Centre website (www.africacen-
tre.ac.za) or by contacting Ruth Bland at rbland@
africacentre.ac.za . The cohort is an ongoing treatment
cohort in partnership with the DoH, and relevant eth-
ical approval is sought for all collaborative work. We
are currently in the process of obtaining ethical per-
mission to contribute data to the International epide-
miologic Databases to Evaluate AIDS (IeDEA)
Southern Africa (IeDEA-SA) collaboration (http://
www.iedea-hiv.org/).
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